patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_508784 | REC_0017301 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 10.3 | 63 | male | 0 | 20 | 5.6 | 1 | osimertinib 80 mg daily | 17.8 | true | MSI-H | 2026-03-15T05:36:02.109496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295180 | REC_0017302 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8 | 66 | female | 1 | 28 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:02.109801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594535 | REC_0017303 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 6.7 | 47 | female | 0 | 22 | 4.2 | 5 | osimertinib 80 mg daily | 10.4 | false | MSS | 2026-03-15T05:36:02.110094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611476 | REC_0017304 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 4 | 49 | female | 0 | 13 | 5.2 | 8 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:02.110536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664919 | REC_0017305 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.9 | 61 | female | 1 | 18 | 5.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.2 | true | MSS | 2026-03-15T05:36:02.110864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403704 | REC_0017306 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.3 | 79 | female | 2 | 12 | 6.7 | 7 | pembrolizumab 200 mg q3w | 12.3 | false | MSS | 2026-03-15T05:36:02.111133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330157 | REC_0017307 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.3 | 70 | female | 1 | 11 | 6.9 | 6 | alectinib 600 mg BID | 7 | false | MSI-H | 2026-03-15T05:36:02.111393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209541 | REC_0017308 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 9.2 | 62 | male | 0 | 9 | 5.6 | 1 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:36:02.111672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544702 | REC_0017309 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 8.5 | 72 | female | 1 | 4 | 6.3 | 3 | osimertinib 80 mg daily | 15.5 | false | MSS | 2026-03-15T05:36:02.111963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828947 | REC_0017310 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 16 | 22.4 | 62 | female | 1 | 10 | 6 | 0 | osimertinib 80 mg daily | 27.1 | false | MSS | 2026-03-15T05:36:02.113727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681675 | REC_0017311 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 13 | 72 | female | 3 | 0 | 4.9 | 4 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:36:02.114117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122500 | REC_0017312 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.1 | 67 | female | 0 | 21 | 6.3 | 7 | osimertinib 80 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:36:02.114498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521892 | REC_0017313 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 8.9 | 77 | female | 3 | 49 | 6.1 | 4 | pembrolizumab 200 mg q3w | 20.6 | true | MSS | 2026-03-15T05:36:02.114842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936275 | REC_0017314 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 11.3 | 65 | female | 0 | 8 | 7 | 7 | sotorasib 960 mg daily | 18.4 | false | MSI-H | 2026-03-15T05:36:02.115290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479897 | REC_0017315 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 9.2 | 57 | male | 0 | 45 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.3 | true | MSS | 2026-03-15T05:36:02.115665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933353 | REC_0017316 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 16.5 | 76 | female | 1 | 14 | 6.5 | 3 | sotorasib 960 mg daily | 10 | true | MSI-H | 2026-03-15T05:36:02.116025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275560 | REC_0017317 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.8 | 54 | female | 0 | 11 | 8.9 | 4 | entrectinib 600 mg daily | 10 | false | MSS | 2026-03-15T05:36:02.116771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557332 | REC_0017318 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.5 | 65 | female | 0 | 18 | 4.1 | 9 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:02.117266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953670 | REC_0017319 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 4.4 | 68 | male | 1 | 22 | 5.1 | 2 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:36:02.117728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391562 | REC_0017320 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 15.9 | 58 | female | 0 | 9 | 6.6 | 7 | entrectinib 600 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:36:02.118201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396527 | REC_0017321 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 13 | 15.6 | 70 | male | 1 | 17 | 3.2 | 1 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:36:02.118652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510922 | REC_0017322 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.7 | 65 | male | 0 | 17 | 7.8 | 5 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:36:02.119047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194104 | REC_0017323 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 9.4 | 61 | male | 0 | 24 | 4.4 | 7 | pembrolizumab 200 mg q3w | 7.6 | false | MSS | 2026-03-15T05:36:02.122541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270489 | REC_0017324 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.3 | 60 | male | 0 | 8 | 2.3 | 4 | entrectinib 600 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:02.122931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913412 | REC_0017325 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12.7 | 65 | female | 1 | 10 | 5.3 | 7 | osimertinib 80 mg daily | 10.8 | false | MSS | 2026-03-15T05:36:02.123251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429356 | REC_0017326 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 8.5 | 55 | male | 1 | 17 | 5.3 | 1 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:36:02.123588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710514 | REC_0017327 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 12.4 | 49 | female | 0 | 19 | 4.9 | 2 | pembrolizumab 200 mg q3w | 23.5 | false | MSI-H | 2026-03-15T05:36:02.123914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812569 | REC_0017328 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11 | 62 | female | 0 | 17 | 5.8 | 7 | alectinib 600 mg BID | 14 | false | MSS | 2026-03-15T05:36:02.124365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859696 | REC_0017329 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 15.9 | 62 | female | 1 | 26 | 5.7 | 3 | sotorasib 960 mg daily | 5 | false | MSS | 2026-03-15T05:36:02.124767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842519 | REC_0017330 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 11.2 | 75 | female | 2 | 10 | 5 | 7 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:36:02.125275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290890 | REC_0017331 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 28 | 10.3 | 68 | female | 0 | 14 | 5.1 | 0 | entrectinib 600 mg daily | 23.5 | false | MSS | 2026-03-15T05:36:02.125619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648401 | REC_0017332 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12.1 | 73 | female | 1 | 15 | 6.7 | 1 | osimertinib 80 mg daily | 22.2 | true | MSS | 2026-03-15T05:36:02.125949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716347 | REC_0017333 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 10.4 | 59 | female | 1 | 1 | 5 | 8 | osimertinib 80 mg daily | 5.4 | true | MSS | 2026-03-15T05:36:02.126317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225173 | REC_0017334 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.6 | 55 | male | 0 | 16 | 5.6 | 2 | sotorasib 960 mg daily | 18.3 | true | MSS | 2026-03-15T05:36:02.126699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888237 | REC_0017335 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 6.4 | 84 | female | 1 | 42 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:36:02.127070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244586 | REC_0017336 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8.8 | 65 | male | 1 | 14 | 5.8 | 5 | alectinib 600 mg BID | 5.6 | false | MSS | 2026-03-15T05:36:02.127492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322701 | REC_0017337 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 11.7 | 75 | female | 2 | 14 | 5.9 | 6 | pembrolizumab 200 mg q3w | 9.4 | false | MSI-H | 2026-03-15T05:36:02.128308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823196 | REC_0017338 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.1 | 67 | female | 0 | 39 | 7 | 7 | pembrolizumab 200 mg q3w | 9.5 | true | MSS | 2026-03-15T05:36:02.128639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171797 | REC_0017339 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 12.1 | 69 | female | 0 | 21 | 6 | 0 | sotorasib 960 mg daily | 48.4 | true | MSI-H | 2026-03-15T05:36:02.128970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938723 | REC_0017340 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 11 | 51 | female | 0 | 13 | 5.7 | 1 | osimertinib 80 mg daily | 20.1 | false | MSI-H | 2026-03-15T05:36:02.129382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584788 | REC_0017341 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 8.1 | 72 | female | 1 | 14 | 5 | 2 | osimertinib 80 mg daily | 23.1 | false | MSS | 2026-03-15T05:36:02.129749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288706 | REC_0017342 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 6.8 | 82 | female | 2 | 15 | 5.7 | 2 | alectinib 600 mg BID | 17.6 | false | MSS | 2026-03-15T05:36:02.130089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497606 | REC_0017343 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.3 | 73 | female | 2 | 30 | 5.6 | 2 | pembrolizumab 200 mg q3w | 15.6 | false | MSS | 2026-03-15T05:36:02.130686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439942 | REC_0017344 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 5 | 69 | female | 1 | 8 | 5.2 | 1 | alectinib 600 mg BID | 22.9 | true | MSS | 2026-03-15T05:36:02.131256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624464 | REC_0017345 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 10.7 | 68 | female | 1 | 12 | 4.5 | 2 | alectinib 600 mg BID | 21.1 | false | MSI-H | 2026-03-15T05:36:02.131729+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403218 | REC_0017346 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 5.9 | 72 | male | 1 | 7 | 6.4 | 2 | osimertinib 80 mg daily | 8.2 | false | MSS | 2026-03-15T05:36:02.132294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364830 | REC_0017347 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 16.9 | 72 | female | 3 | 3 | 7.4 | 1 | entrectinib 600 mg daily | 20 | false | MSI-H | 2026-03-15T05:36:02.132793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699150 | REC_0017348 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.2 | 88 | female | 2 | 13 | 4.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 12 | false | MSS | 2026-03-15T05:36:02.133188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889708 | REC_0017349 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.3 | 71 | female | 2 | 1 | 5.8 | 3 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:36:02.133574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184833 | REC_0017350 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.2 | 62 | female | 0 | 38 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.7 | false | MSS | 2026-03-15T05:36:02.133929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778513 | REC_0017351 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 18.3 | 71 | female | 3 | 13 | 4.2 | 1 | osimertinib 80 mg daily | 6.1 | false | MSI-H | 2026-03-15T05:36:02.134273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984204 | REC_0017352 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.8 | 72 | female | 1 | 13 | 5.9 | 1 | sotorasib 960 mg daily | 19.4 | true | MSS | 2026-03-15T05:36:02.134620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344639 | REC_0017353 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 16 | 57 | male | 0 | 11 | 3.8 | 0 | entrectinib 600 mg daily | 12.3 | true | MSS | 2026-03-15T05:36:02.134956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576126 | REC_0017354 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.2 | 60 | female | 1 | 15 | 4.7 | 10 | osimertinib 80 mg daily | 8.3 | true | MSS | 2026-03-15T05:36:02.135261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153047 | REC_0017355 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 3.9 | 71 | male | 2 | 22 | 5.2 | 2 | pembrolizumab 200 mg q3w | 11.2 | true | MSS | 2026-03-15T05:36:02.135589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786455 | REC_0017356 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 14.8 | 66 | female | 0 | 18 | 5.2 | 7 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:36:02.136240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901524 | REC_0017357 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 6.6 | 62 | female | 0 | 5 | 7.9 | 5 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:36:02.136699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282238 | REC_0017358 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.4 | 76 | female | 1 | 33 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.3 | false | MSS | 2026-03-15T05:36:02.137071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970959 | REC_0017359 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 16 | 6.3 | 66 | female | 1 | 4 | 6.2 | 7 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:02.137418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895641 | REC_0017360 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 10.4 | 63 | female | 0 | 45 | 6 | 3 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:36:02.137768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318284 | REC_0017361 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.7 | 83 | female | 2 | 15 | 7.4 | 2 | osimertinib 80 mg daily | 8.8 | true | MSS | 2026-03-15T05:36:02.138107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487007 | REC_0017362 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.6 | 53 | male | 0 | 19 | 4.4 | 8 | alectinib 600 mg BID | 17 | true | MSI-H | 2026-03-15T05:36:02.138451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721349 | REC_0017363 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 5.6 | 65 | female | 1 | 12 | 5.1 | 8 | pembrolizumab 200 mg q3w | 19.7 | false | MSS | 2026-03-15T05:36:02.138762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613224 | REC_0017364 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 9.4 | 62 | male | 1 | 16 | 3.8 | 7 | osimertinib 80 mg daily | 14 | false | MSS | 2026-03-15T05:36:02.139101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280324 | REC_0017365 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 16.4 | 66 | female | 0 | 21 | 5.4 | 1 | osimertinib 80 mg daily | 23.1 | true | MSI-H | 2026-03-15T05:36:02.139435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763006 | REC_0017366 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 7.7 | 42 | female | 0 | 49 | 4.9 | 4 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:02.139762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794092 | REC_0017367 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 8.6 | 61 | female | 0 | 21 | 5 | 4 | alectinib 600 mg BID | 8 | true | MSS | 2026-03-15T05:36:02.141618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422475 | REC_0017368 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 3.1 | 73 | female | 2 | 33 | 4.1 | 1 | pembrolizumab 200 mg q3w | 15.6 | true | MSS | 2026-03-15T05:36:02.142149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992725 | REC_0017369 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 8.2 | 83 | female | 1 | 18 | 3.9 | 7 | entrectinib 600 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:02.142708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155478 | REC_0017370 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12.9 | 79 | male | 1 | 16 | 5.1 | 1 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:36:02.143110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436712 | REC_0017371 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 10.3 | 64 | male | 0 | 10 | 5.2 | 2 | sotorasib 960 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:36:02.143449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874809 | REC_0017372 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 17.6 | 68 | female | 1 | 22 | 6 | 7 | alectinib 600 mg BID | 10.2 | false | MSS | 2026-03-15T05:36:02.143797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724527 | REC_0017373 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 13.1 | 54 | female | 0 | 20 | 5 | 2 | entrectinib 600 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:02.144217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914075 | REC_0017374 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 15.7 | 61 | male | 1 | 5 | 6 | 2 | entrectinib 600 mg daily | 26.7 | false | MSS | 2026-03-15T05:36:02.144596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729937 | REC_0017375 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 22.3 | 69 | female | 1 | 18 | 4.5 | 4 | entrectinib 600 mg daily | 5.6 | false | MSI-H | 2026-03-15T05:36:02.144960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974152 | REC_0017376 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.6 | 82 | female | 2 | 57 | 4.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.8 | false | MSS | 2026-03-15T05:36:02.145298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309875 | REC_0017377 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.3 | 82 | female | 2 | 77 | 4.8 | 10 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:36:02.145666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299021 | REC_0017378 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 14.1 | 70 | female | 1 | 19 | 7.2 | 2 | sotorasib 960 mg daily | 23.2 | true | MSI-H | 2026-03-15T05:36:02.146053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288906 | REC_0017379 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 8 | 68 | female | 0 | 12 | 5.8 | 5 | entrectinib 600 mg daily | 9.1 | true | MSS | 2026-03-15T05:36:02.146431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553735 | REC_0017380 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 8.7 | 58 | male | 0 | 19 | 7.6 | 5 | alectinib 600 mg BID | 4.9 | false | MSS | 2026-03-15T05:36:02.146803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456988 | REC_0017381 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 20 | 2.5 | 59 | female | 0 | 14 | 3.1 | 0 | osimertinib 80 mg daily | 25.3 | false | MSS | 2026-03-15T05:36:02.147168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332711 | REC_0017382 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 14.4 | 70 | female | 0 | 16 | 4.3 | 6 | sotorasib 960 mg daily | 9.7 | false | MSS | 2026-03-15T05:36:02.147805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586984 | REC_0017383 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.8 | 79 | female | 2 | 21 | 4.5 | 4 | pembrolizumab 200 mg q3w | 9 | true | MSS | 2026-03-15T05:36:02.148352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400402 | REC_0017384 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 13.7 | 75 | female | 2 | 9 | 6.2 | 1 | sotorasib 960 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:36:02.148805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339618 | REC_0017385 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 22.9 | 69 | female | 1 | 19 | 5.1 | 3 | osimertinib 80 mg daily | 11.2 | false | MSS | 2026-03-15T05:36:02.149202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690667 | REC_0017386 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.9 | 64 | male | 1 | 13 | 5.8 | 8 | alectinib 600 mg BID | 8.1 | false | MSS | 2026-03-15T05:36:02.154581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962114 | REC_0017387 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 13.9 | 69 | female | 0 | 7 | 5.5 | 5 | pembrolizumab 200 mg q3w | 12.6 | false | MSI-H | 2026-03-15T05:36:02.155123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929613 | REC_0017388 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.7 | 67 | female | 0 | 62 | 5.7 | 6 | pembrolizumab 200 mg q3w | 7.2 | false | MSS | 2026-03-15T05:36:02.155503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696609 | REC_0017389 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 9.8 | 64 | female | 1 | 15 | 3.2 | 8 | pembrolizumab 200 mg q3w | 16.6 | false | MSS | 2026-03-15T05:36:02.155950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300503 | REC_0017390 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 2.9 | 77 | female | 3 | 13 | 4.6 | 8 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:36:02.156728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156245 | REC_0017391 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 7.2 | 71 | female | 2 | 18 | 5 | 7 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:36:02.157129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395415 | REC_0017392 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 7.4 | 63 | male | 0 | 3 | 6.1 | 6 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:02.157476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998122 | REC_0017393 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.3 | 75 | female | 1 | 22 | 5 | 6 | pembrolizumab 200 mg q3w | 10.2 | true | MSS | 2026-03-15T05:36:02.157814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931098 | REC_0017394 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 14.3 | 58 | female | 1 | 19 | 5.2 | 2 | osimertinib 80 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:36:02.158154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317894 | REC_0017395 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 11.3 | 65 | male | 0 | 12 | 5.5 | 6 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:36:02.158720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621787 | REC_0017396 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 9.9 | 76 | female | 2 | 23 | 8 | 6 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:02.159126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344606 | REC_0017397 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 9 | 82 | female | 0 | 14 | 8.4 | 1 | osimertinib 80 mg daily | 29.6 | false | MSS | 2026-03-15T05:36:02.159527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648389 | REC_0017398 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 14 | 13.4 | 79 | female | 2 | 19 | 7 | 3 | alectinib 600 mg BID | 10.6 | false | MSS | 2026-03-15T05:36:02.159890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311012 | REC_0017399 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 10.2 | 71 | female | 1 | 22 | 5.1 | 6 | sotorasib 960 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:02.160398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566921 | REC_0017400 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 10.9 | 67 | male | 0 | 28 | 4.5 | 2 | osimertinib 80 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:36:02.160862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.